PRS-343 in HER2-Positive Solid Tumors
NCT03330561 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 85
Last updated 2024-04-22
Summary
A multi center, open-label, Phase 1 dose escalation study with expansion cohort is designed to determine the MTD, RP2D and dosing schedule of PRS-343 in patients with HER2+ advanced or metastatic solid tumors.
Conditions
- HER2-positive Breast Cancer
- HER2-positive Gastric Cancer
- HER2-positive Bladder Cancer
- HER2-positive Solid Tumor
Interventions
- DRUG
-
PRS-343
PRS-343
Sponsors & Collaborators
-
Pieris Pharmaceuticals, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-13
- Primary Completion
- 2023-12-01
- Completion
- 2023-12-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
NCT05514717 ·Status: RECRUITING ·Phase: PHASE1
-
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
NCT05905341 ·Status: WITHDRAWN ·Phase: PHASE1
-
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT03006172 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)
NCT02286219 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
NCT03393845 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
NCT03927456 ·Status: UNKNOWN ·Phase: PHASE3
-
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
NCT06614751 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors
NCT04146610 ·Status: UNKNOWN ·Phase: PHASE1
-
A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
NCT06470347 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer
NCT03451162 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
NCT06714617 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of DP303c in Patients With HER2-positive Advanced Solid Tumors
NCT05810103 ·Status: UNKNOWN ·Phase: PHASE1
-
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
NCT06057610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer
NCT03696771 ·Status: COMPLETED ·Phase: PHASE1
-
Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer
NCT03971045 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
NCT01684215 ·Status: COMPLETED ·Phase: PHASE2
-
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
NCT03602079 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
NCT03772353 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
NCT05318339 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
NCT00627627 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2
NCT00199212 ·Status: COMPLETED ·Phase: PHASE1